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Major histocompatibility complex class II (MHCII) proteins are loaded with endosomal
peptides and reside at the surface of antigen-presenting cells (APCs) for a time before
being degraded. In vitro, MHCII protein levels and turnover are affected by peptide load-
ing and by rates of ubiquitin-dependent internalization from the cell surface, which is in
turn affected by APC type and activation state. Prior work suggested that fast turnover of
disease-associated MHCII alleles may contribute to autoimmunity. We recently developed
novel stable isotope tracer techniques to test this hypothesis in vivo. In non-obese dia-
betic (NOD) mice, a model of type 1 diabetes (T1D), MHCII turnover was affected by APC
type, but unaffected by disease-associated structural polymorphism. Differences in MHCII
turnover were observed between NOD colonies with high and lowT1D incidence, but fast
turnover was dispensable for autoimmunity. Moreover, NOD mice with gene knockouts of
peptide loading cofactors do not develop T1D. Thus, fast turnover does not appear path-
ogenic, and conventional antigen presentation is critical for autoimmunity in NOD mice.
However, shared environmental factors may underpin colony differences in MHCII protein
turnover, immune regulation, and pathogenesis.
Keywords: autoimmune pathogenesis, type 1 diabetes mellitus, major histocompatibility complex class II,
antigen-presenting cell, protein turnover, mass spectrometry
INTRODUCTION
Major histocompatibility complex class II (MHCII) molecules
present peptides at cell surfaces for recognition by CD4+ T lym-
phocytes. They shape a functional, self-tolerant T-cell repertoire
via positive and negative thymocyte selection and support periph-
eral CD4+ T-cell homeostasis (1). Presentation of pathogen-
derived peptides activates specific CD4 T cells, initiating adaptive
immunity (2). Extensive polymorphism in the peptide-binding
groove, shaping the presented peptide repertoire, is a key charac-
teristic of MHCII proteins (3). These polymorphisms also control
susceptibility to autoimmune diseases.
The regulation of MHCII protein expression is critical to these
functions. Here, we discuss MHCII protein turnover, a critical
but poorly understood determinant of steady-state expression.
We describe recent methodological advances in measuring MHCII
protein turnover in vivo, which enabled us to examine the postu-
lated role of MHCII protein turnover in autoimmune pathogenesis
in a mouse model.
FUNCTIONAL SIGNIFICANCE OF MHCII PROTEIN TURNOVER
Major histocompatibility complex class II proteins are expressed
constitutively by antigen-presenting cells [APCs: B cells, dendritic
cells (DCs), macrophages, thymic epithelial cells] and inducibly
by other cell types. MHCII gene transcription is controlled by
the master regulator, class II transactivator (CIITA) (4). Post-
translational regulation fine-tunes MHCII expression levels and
determines antigen persistence. For example, in DCs, CIITA, and
MHCII gene transcription are shut down following activation by
bacterial lipopolysaccharide, yet MHCII surface levels rise, because
MHCII protein degradation is also shut down (5). As a result,
long-lived MHCII/peptide complexes are able to survive during
DC migration to lymph nodes (6), where they provide persis-
tent stimuli for CD4+ T-cell priming (7). In other APC types,
cytokine regulation of MHCII turnover also affects expression
(8, 9), and stimuli can increase turnover, rather than shutting
it down.
DETERMINANTS OF MHCII PROTEIN TURNOVER
Major histocompatibility complex class II degradation in non-
activated DCs begins with internalization from the cell surface,
which is triggered by ubiquitination of the cytoplasmic tail of
the MHCII β chain (10) by the ubiquitin E3 ligase, membrane-
associated RING-CH 1 (MARCH-1) (11, 12). The α chain is also
ubiquitinated to a small extent (13). When activated by proin-
flammatory stimuli, conventional DCs downregulate MARCH-1,
terminating MHCII protein turnover; in contrast, activated plas-
macytoid DCs maintain this process (14). MARCH-1 also medi-
ates cytokine regulation of MHCII turnover in monocytes and B
cells (8, 9, 15). Other MARCH family members may be involved,
as well (16).
The internalized MHCII molecules are targeted for lysosomal
degradation by unknown proteases. Studies using inhibitors sug-
gest a role for cysteine proteases, although the effects are small
(17) and MHCII molecules resist proteolysis by many cysteine
cathepsins in vitro (18). The serine protease, Cathepsin G, cleaves
MHCII molecules at a specific membrane-proximal site in vitro,
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but this does not detectably contribute to MHCII degradation in
APCs (18).
Major histocompatibility complex class II protein degrada-
tion is also influenced by the preceding assembly and maturation
steps, which are reviewed elsewhere in this series (Figure 1) (19).
Briefly, αβ heterodimers assemble with invariant chain (Ii) in the
endoplasmic reticulum (ER) and travel to endosomes. There, Ii
is cleaved, leaving class II-associated Ii peptides (CLIP) in the
peptide-binding groove, which must be released to enable loading
with endosomal peptides. A co-factor, DM (HLA-DM in humans,
H2-DM/H2-M in mice), releases CLIP, “edits” peptides to select
stable binders, and stabilizes empty MHCII molecules (“chaperon-
ing”). Finally, MHCII/peptide complexes travel from endosomes
to the plasma membrane. Defects in these maturation steps accel-
erate MHCII protein degradation, sometimes by use of alternative
degradation pathways. In Ii-deficient cells, a significant proportion
of MHCII molecules are retained in the ER and degraded (20),
presumably by the proteasome following retrotranslocation to the
cytosol. In DM-deficient cells, the turnover of some MHCII alleles
in post-Golgi compartments is accelerated, likely because MHCII
acquire loosely bound peptides and are not chaperoned follow-
ing spontaneous CLIP release (21). Moreover, peptide occupancy
appears to protect MHCII molecules from degradation even in
normal APCs: exposure of splenocytes to high doses of exogenous
antigen protects MHCII molecules from degradation, increases
their resistance to disruptive detergents (SDS), and raises their
surface levels (22).
Many details of these mechanisms remain ill-defined. More-
over,while polymorphisms may affect MHCII fate in DM-deficient
cells, via their impact on CLIP affinity, it is unclear to what extent
MHCII allelic variants may differ in their turnover rates in normal
APCs.
FIGURE 1 | Major histocompatibility complex class II protein turnover: molecular regulation and mass spectrometric measurement. (A) Regulation of
MHCII protein turnover in APCs. (B)Work flow for SINEW measurement of MHCII protein turnover in mice.
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COULD ACCELERATED MHCII PROTEIN TURNOVER PROMOTE
AUTOIMMUNITY?
A role for MHCII protein turnover in autoimmunity was first pro-
posed in non-obese diabetic (NOD) mice, which develop autoim-
mune beta-islet cell destruction leading to type 1 diabetes (T1D)
under complex genetic, environmental, and developmental con-
trol. The sole expressed MHCII gene product,H2-Ag7, is critical for
T1D development [recently reviewed in detail by Busch et al. (23)].
Ag7 has a unique β chain, differing by 17 amino acids from Aβd;
its α chain is identical to Aαd. Ag7 shares structural features with
HLA-DQ alleles associated with T1D in humans, including a key
non-Asp57β polymorphism, affecting the P9 specificity pocket.
One reason to suspect that Ag7 polymorphisms confer a broader
structural deficit is that Ag7-restricted autoreactivity in NOD mice
is not islet-specific. Crossing NOD mice with KRN T-cell receptor
transgenic mice serendipitously creates reactivity to a ubiqui-
tously expressed, Ag7-presented self peptide, triggering autoim-
mune arthritis (24). Moreover, NOD mice exhibit spontaneous
autoreactivity (25), and immunization with foreign antigens elicits
Ag7-restricted bystander responses to self peptides (26). Numer-
ous unusual biochemical features of Ag7 might contribute to the
tolerance deficits (Figure 2A):
• Numerous peptides bind weakly to, or dissociate rapidly from,
Ag7 (27–30). Peptide binding to Ag7 may be unusually promis-
cuous (31).
• Ag7 has low CLIP affinity at endosomal pH (32). Paradoxi-
cally, CLIP levels on NOD splenocytes are high (33), suggesting
inefficient DM editing in vivo, which could diminish the levels
or stability of Ag7 complexes with self peptides and accelerate
turnover (21, 34). The reason is unclear, as Ag7 seems to interact
productively with DM in transfectants (35). Unstable peptide
binding may be determined extrinsically, rather than by Ag7
structural polymorphism.
• One study has shown unusually fast turnover of Ag7 in NOD
splenocytes in vitro (27).
• Ag7 heterodimers dissociate at room temperature in the presence
of SDS detergent (27), more so than other H-2A alleles. This fea-
ture is shared by human DQ T1D risk alleles (36). Although its
significance is unclear, SDS instability could correlate with some
of the other biochemical features described above.
Other studies, however, questioned the relevance of these find-
ings to pathogenesis. The SDS instability of Ag7 may represent
the lower range of normal variation (37). Not all studies found
defects in peptide binding selectivity or life span of Ag7 (37,
38). Studies of soluble recombinant Ag7 provided no evidence
for stability defects (39, 40). Lastly, the biochemistry of Ag7 dif-
fers from that of the homologous human HLA-DQ T1D risk
alleles, DQ2 and DQ8, in key details (e.g., the mechanism of
CLIP retention (41), so these details may not be critical for
pathogenesis.
Peptide-specific mechanisms for Ag7-restricted autoreactivity
have also been proposed. Ag7 selects peptides similar to those
binding human DQ T1D risk alleles (38). Neo-self determi-
nants may be generated by post-translational modification of
peptides by transglutaminases, resulting in increased binding to
Ag7 (42), analogous to mechanisms explaining DQ associations
with celiac disease in humans (23). Both peptide-dependent and
-independent mechanisms could contribute to Ag7 associations
with autoimmunity.
IN VIVO MEASUREMENTS OF PROTEIN TURNOVER:
A METHODOLOGICAL EXCURSION
Given these uncertainties, we re-examined whether Ag7 molecules
exhibit unusually fast turnover in NOD mice, and what this meant
for autoimmunity. We also quantified the baseline turnover of
MHCII molecules in APCs of normal mice for the first time. This
FIGURE 2 | Possible roles of accelerated Ag7 protein turnover in
autoimmune pathogenesis in NOD mice. (A) Model adapted from (26) and
(27), linking Ag7 polymorphism to intrinsic stability defects, accelerated
turnover, impaired T-cell tolerance, and increased risk of autoimmunity.
(B) Revised model, based on (53), showing accelerated Ag7 turnover in vivo to
be regulated, independently of structural polymorphisms and SDS instability,
by unknown environmental factors, with either a neutral or inhibitory role in
autoimmune pathogenesis.
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required the development of novel methods for measuring MHCII
protein turnover in vivo.
Protein turnover is measured using tracers, which are biosyn-
thetically incorporated into newly synthesized proteins and persist
until the protein is degraded. In cell culture, newly synthesized
proteins may be tagged with radiolabeled amino acids (e.g., [35S]-
Met/Cys); during a subsequent chase, the fate of the labeled
proteins is tracked by autoradiography (43). This approach is pow-
erful but difficult to use in vivo, because substantial amounts of
radioactivity would be required, even in small-animal models.
Stable isotope tracers, lacking radiation hazards, are easier to
use in vivo. “SILAC” (stable isotope labeling of amino acids in cell
culture), used for kinetics rather than quantitation, is one variant
of this approach (44). Arg and Lys in culture media are replaced
with all-[13C]-Arg/Lys, and their incorporation into newly syn-
thesized proteins is quantified by mass spectrometric analysis of
tryptic digests. The relative abundances of unlabeled and labeled
peptides define the proportion of molecules that were synthesized
during the labeling interval and survived until analysis (“fractional
protein synthesis”). The approach has been adapted for in vivo use
(45). However, label entry into amino acyl-tRNAs used for protein
synthesis is not fully understood; pools of unlabeled amino acids
may persist in animals even after long-term labeling.
An alternative strategy uses deuterated water (2H2O) as a
biosynthetic label. 2H2O labeling is simple and inexpensive to
perform in cell culture and in vivo (46). At levels used for meta-
bolic labeling (1–5% in body water), 2H2O does not interfere with
normal physiology. It rapidly equilibrates throughout the body fol-
lowing administration. Protons from water are used primarily in
the (comparatively rapid) synthesis of non-essential amino acids,
such as Ala, by cells (47). For proteins with turnover rates of a few
hours or longer, protein synthesis is the rate-limiting step for 2H
label incorporation from 2H2O (48, 49). This approach was named
“SINEW” (stable isotope labeling of non-essential amino acids
with heavy water). Like SILAC, SINEW tracks the proportions
of unlabeled to labeled tryptic peptides by mass spectrometry.
Although these species are less well resolved in SINEW experi-
ments, precise measurements of fractional protein synthesis rates
are possible (50–52).
New protein is synthesized not only to replace protein lost to
turnover, but also to maintain protein levels as cells divide. For cell-
associated proteins with slow turnover rates, the proliferative con-
tribution can be considerable. During SINEW experiments, this
contribution can be quantified accurately by measuring 2H incor-
poration from 2H2O into newly synthesized DNA (46). SINEW
was therefore used to explore MHCII protein turnover (53).
EXTRINSIC REGULATION OF MHCII PROTEIN TURNOVER
IN VIVO
To quantify Ag7 protein turnover in vivo (53), we labeled young
female prediabetic NOD mice with 2H2O; BALB/c mice (Ad, Ed)
were used as controls. MHCII molecules were immunoprecipi-
tated from splenic B cells and DCs (which together harbor most
splenic MHCII molecules), resolved on SDS gels, digested with
trypsin, and analyzed by mass spectrometry. MHCII-derived pep-
tides were identified, and changes in their mass distributions from
2H2O labeling were used to quantify fractional protein synthesis
(Figure 1B). MHCII protein synthesis greatly exceeded the rate
required to support the turnover of the APCs themselves (quanti-
fied by analysis of 2H incorporation into DNA). Thus, fractional
protein synthesis reflected MHCII protein turnover rates.
The turnover rates of MHCII proteins in vivo proved to be
markedly affected by the cellular microenvironment: turnover
half-lives (t 1/2) were ≈10–12 h in B cells but twice as fast (t 1/2
≈5–6 h) in DCs (53). Thus, turnover rates measured in unsepa-
rated splenocytes (27) might be somewhat confounded by differ-
ences in APC composition, because NOD splenocytes contained
a greater proportion of DCs, relative to B cells, than BALB/c
splenocytes. Other APC types or locations of potential relevance
to pathogenesis were not analyzed here.
Given that inflammatory stimuli influence MHCII protein
turnover rates (5), it should be noted that these experiments
were performed in specific pathogen-free mice, which exhib-
ited no detectable activation of splenic APCs; conceivably, altered
MHCII protein turnover in a few activated APCs might be rele-
vant to pathogenesis. The difference in MHCII half-lives between
APC types may reflect the greater extent of ubiquitination and
internalization of MHCII molecules in DCs (54).
We also examined Ag7 turnover in transfected M12 B lym-
phoma cells (50, 53). These cells doubled approximately every
27 h and produced new Ag7 molecules at the same rate. Thus,
Ag7 protein synthesis was attributable to cell growth, with only a
small contribution from turnover. The implied long Ag7 half-life
(>2 days) argues against an intrinsic stability deficit of this allele
and confirms a substantial impact of the cellular microenviron-
ment on MHCII turnover rates. These findings also indicated that
physiological turnover rates are not necessarily recapitulated in
model cell lines.
Within each cell type, MHCII alleles apparently differed in their
dynamics (53): the half-life of Ag7 molecules in NOD B cells was
significantly shorter than that of Ad in BALB/c B cells, albeit by only
a small amount (13%). However, kinetic modeling indicated that
that Ag7 turnover was heterogeneous: its 2H2O labeling curve was
significantly better explained by a mixture of long- and short-lived
molecules than by a uniform half-life.
The presence in NOD (but not BALB/c) B cells of some
H2-A molecules with faster turnover could reflect strain differ-
ences in the cellular microenvironment. To address this, we bred
(NOD×BALB/c) F1 mice, expressing both H2-A molecules in the
same cells. In F1 APCs, the turnover of Ad and Ag7 was indistin-
guishable (53), so the cellular microenvironment is decisive. The
fast-turnover component may be attributable to inefficient pep-
tide loading in NOD splenocytes, although this is not the only
possible explanation.
ACCELERATED AG7 TURNOVER IS DISPENSABLE FOR
AUTOIMMUNITY
Several observations suggested that fast-turnover Ag7 molecules
do not correlate closely with T1D development (53). Ag7 turnover
is indistinguishable between B cells from male and female NOD
mice, yet T1D incidence is lower in males. Moreover, the fast-
turnover subpopulation detectable in young female NOD mice
becomes undetectable at 12 weeks of age, prior to the onset
of T1D.
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More compellingly, we initially observed the fast-turnover Ag7
molecules in one colony of NOD mice, which exhibited a rela-
tively low incidence of T1D (22% diabetic females at 30 weeks of
age). When we repeated the SINEW experiments in a second NOD
colony, which develops a much higher T1D incidence (>80% at
30 weeks in females), its Ag7 molecules showed no accelerated
turnover (53). Thus, fast Ag7 turnover appears dispensable for
T1D development (Figure 2B).
This conclusion might seem disappointing, yet our findings
may harbor a critical clue. Worldwide, NOD colonies differ widely
in their disease incidence as a result of unknown environmen-
tal variables (55); our two colonies represent extremes on this
spectrum. The environmental regulator(s) in our colony remain
unknown but appear to be novel. Our results suggest, however,
that key environmental influences may be sensed by B cells in sec-
ondary lymphoid organs, triggering changes in the dynamics of
antigen presentation (Figure 2B). Dissection of these mechanisms
may yield novel insights into mechanisms of gut microbe/immune
interactions in autoimmunity.
NORMAL MHCII PEPTIDE LOADING REQUIRED FOR
AUTOIMMUNITY IN NOD MICE
Intact MHCII peptide loading pathways are critical to T1D patho-
genesis in NOD mice. Invariant (Ii) chain-deficient NOD mice
express reduced levels of Ag7 and are protected from T1D (56).
Their effector CD4+ T cells have islet autoreactivity similar to
Ii-sufficient NOD mice, but the frequency of regulatory T cells
(Tregs) is increased (57). Similarly, DM-deficient NOD mice show
reduced Ag7 surface expression and are protected from T1D devel-
opment (58). These mice also have increased Treg frequencies but,
unlike Ii-null NOD mice, do not develop autoreactive effector T
cells, suggesting that presentation of islet autoantigens requires
peptide editing. A more subtle defect was engineered into DCs
of NOD mice by transgenic expression of HLA-DO, an inhibitor
of DM, under control of the CD11c promoter (59). These mice
also failed to develop T1D, indicating an important role of normal
MHCII peptide editing in DCs during T1D pathogenesis. Because
defects in MHCII peptide loading pathways accelerate Ag7 protein
turnover (21, 34), the findings are consistent with our observations
that fast-turnover Ag7 molecules are dispensable for autoimmu-
nity (53). Indeed, the increased Treg frequencies caused by peptide
loading defects raise the possibility that short-lived Ag7 might be
protective.
CONCLUSION
Turnover rates of MHCII molecules in vivo depend strongly on
APC type and are affected by environmental factors, but not
substantially by the MHCII structural polymorphisms we have
examined. Whether MHC protein turnover is generally insensi-
tive to structural polymorphism in normal APCs is an interesting
question, given the allelic differences previously observed in the
presence of peptide loading defects. Work is ongoing to extend
these observations, explore their functional and evolutionary sig-
nificance, and examine the underlying molecular mechanisms.
Accelerated Ag7 turnover in NOD spleens affects only a subset
of Ag7 molecules and does not represent an intrinsic stability
defect associated with this risk allele. Moreover, this phenotype
is dispensable for autoimmune pathogenesis, and might even
counteract autoimmunity (though the latter possibility will be
difficult to prove). Surprisingly, colony differences in Ag7 turnover
reveal novel potential connections between environmental regula-
tors, B cells, and autoimmune pathogenesis, which are now being
explored. Lastly, SINEW, used here to quantify MHCII protein
turnover, has important advantages in quantifying the turnover
of cell-associated proteins. SINEW shows promise for probing
genotype/phenotype associations and normal and pathological
immune responses.
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